Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURALIO in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors
NCT02390752Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2015
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pexidartinib in solid tumor, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 4 more, sponsored by National Cancer Institute. Primary endpoint: Recommended Phase II Dose. Started Apr 2015; status: recruiting.
02
Drugs
pexidartinib
03
Conditions
solid tumoracute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)neurofibromatosis type 1 (NF1)malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT02390752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390752.